Get started
Author

Mayas Singh

Observed name: Singh, Mayas
ORCID: 0000-0002-5960-9449
Observed ORCID: 0000-0002-5960-9449
OpenAlex ID: A5001185641
Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria
2024 · Lukas Junk, Volker M. Schmiedel, et al. · Nature Communications · 52
PDF
A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters
2023 · Rajeev Mehla, Prasad Kokate, et al. · Vaccines · 16
PDF
Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.
2023 · Geraldine Nadya Putri, Chandra Sekhar Gudla, et al. · Antiviral Research · 14
Design and synthesis of diphenyl-1H-imidazole analogs targeting Mpro/3CLpro enzyme of SARS-CoV-2
2024 · Amisha Vora, Ashish Kanhed, et al. · Medicinal Chemistry Research · 5
PDF
Novel Baicalein-Derived Inhibitors of Plasmodium falciparum
2023 · Chandra Sekhar Gudla, Vignesh Selvam, et al. · Pathogens · 5
PDF
Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria
2025 · Minh-Vu H. Nguyen, Michel Plattner, et al. · EBioMedicine · 2
Apramycin kills replicating and non-replicating Mycobacterium tuberculosis
2024 · Parvinder Kaur, Ramya V. K., et al. · Frontiers in Tropical Diseases · 1
PDF
Design and synthesis of Diphenyl-1H-imidazole analogs towards SARS CoV-2 3CLpro inhibition for the treatment of COVID-19
2023 · Ashish M. Kanhed, Amisha Vora, et al. · Research Square · 1
PDF
FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo
2026 · Gudepalya Renukaiah Rudramurthy, Chandra Sekhar Gudla, et al. · Antiviral Research
Works count: 10
Citation count: 96
H-index: 5
I10-index: 3
Year
Topic
Type